Galiellalactone Is a Direct Inhibitor of the Transcription Factor STAT3 in Prostate Cancer Cells
Nicholas Don‐Doncow(Lund University), Rebecka Hellsten(Lund University)
Cited by 91
Related Papers
The STAT3 inhibitor galiellalactone inhibits the generation of MDSC‐like monocytes by prostate cancer cells and decreases immunosuppressive and tumorigenic factors
|The Prostate|2019|70
Inhibition of STAT3 augments antitumor efficacy of anti-CTLA-4 treatment against prostate cancer
|Cancer Immunology Immunotherapy|2021|33
STAT3 inhibition with galiellalactone effectively targets the prostate cancer stem-like cell population
|Scientific Reports|2020|27